However, CEBPβ expression was not modified either by IDH1 mutation or 2-HG-treatment (Supplementary Figure S3A–C), suggesting that VDR pathway enhancement is regulated through CEBPα rather than CEBPβ in IDHMUT AML. The gene discussed is VDR; the disease is acute myeloid leukemia.